Efficacy Of Erythromycin Phonophoresis on Chronic Rhinosinusitis

ConditionChronic Rhinosinusitis

Trial statusNot yet recruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age25-50

SponsorCairo University

About this trial

The purpose of the study is to evaluate the therapeutic effect of erythromycin phonophoresis in reducing chronic rhinosinusitis.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age range between 25-50 years.

Male and female patients will participate in the study.

All patients have chronic rhinosinusitis.

All patients enrolled in the study will have their informed consent.

Disqualifiers

Patients with pacemaker

Patients diagnosed with cancer.

Pregnant women

Patients with impaired vascular circulation

Trial design

Design model

Parallel

Treatments tested in this trial

Erythromycin Phonophoresis
Other intervention
The procedures of ultrasound phonophoresis will be as follows: Patients will be positioned comfortably, sitting in a relaxed position. The physiotherapist will explain the treatment procedures to the patient. The device cables will be checked before each session. The treatment will last 5 minutes for each maxillary sinus. The frequency will be set to 1 MHz, and the intensity will be 1 W/Cm2 for the maxillary sinuses. The ultrasound will be pulsed, and the treatment will consist of 12 sessions, 3 days per week.
Ultrasound (US)
Device
Therapeutic US is produced by a transducer composed of a piezoelectric crystal, which converts electric energy into alternating compression and rarefaction of sound waves at a frequency greater than 20 kHz. The amplitude of the US wave is proportional to the displacement of the US transducer head during each half cycle. The amplitude represents the wave energy. The ultrasound waves penetrate the tissue on the way to the target organ and have two mechanisms of action (thermal and non-thermal), which may potentially work synergistically to reduce nasal symptoms (nasal blockage and secretions).
Topical Erythromycin
Drug
Erythromycin is a 14-member macrolide originally discovered in the 1950s. It has broad-spectrum antimicrobial action, inhibiting bacterial protein synthesis. studies have shown that erythromycin has immunomodulatory and anti-inflammatory activity independent of its antimicrobial action Erythromycin is a broad-spectrum macrolide antibiotic, wherein its bactericidal effect occurs by the inhibition of protein synthesis. It is used for the treatment of infections affecting the skin and mucosa; it shows immunomodulatory characteristics
Medical treatment
Other intervention
Saline nasal wash 3 times daily for a month.

Treatment groups

90 Participants

are divided into 3 treatment groups

Group A: Erythromycin Phonophoresis + Medical treatmentExperimental treatment 2 interventions

Group B: Ultrasound + Topical Erythromycin + Medical treatmentActive comparator 3 interventions

Group C: Medical treatmentOther 1 intervention

Trial outcomes

Primary outcomes

Sinusitis symptom score (SSS)

Sinusitis Symptom Scores will be based on a visual analogue scale (VAS) well established. In this method, the six symptoms will be assessed using a scale of 0±10, where zero represents no symptom and 10 represents the most severe symptom imaginable

Time frame

one month

Secondary outcomes

Computerized tomography scan (CTS)

CT scan (TOSHIBA, MODEL TSX-035A, INPUT POWER 50kVA), will assess the mucosal thickening of maxillary sinuses

Time frame

one month

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Cairo University

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: